{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T14:33:02Z","timestamp":1792074782534,"version":"4.4.0"},"reference-count":115,"publisher":"Springer Science and Business Media LLC","issue":"5","funder":[{"name":"Leo Pharma"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1007\/s12325-015-0211-7","type":"journal-article","created":{"date-parts":[[2015,5,25]],"date-time":"2015-05-25T10:49:38Z","timestamp":1432550978000},"page":"455-476","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Cost\u2013Utility of First-Line Actinic Keratosis Treatments in Finland"],"prefix":"10.1007","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4259-7610","authenticated-orcid":false,"given":"Erkki J.","family":"Soini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taru","family":"Hallinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna-Leena","family":"Sokka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kari","family":"Saarinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,5,26]]},"reference":[{"key":"211_CR1","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.jaad.2009.02.022","volume":"61","author":"MA Weinstock","year":"2009","unstructured":"Weinstock MA, Lee KC, Chren MM, Marcolivio K, VATTC Trial Group. Quality of life in the actinic neoplasia syndrome: the VA topical tretinoin chemoprevention (VATTC) trial. J Am Acad Dermatol. 2009;61:207\u201315.","journal-title":"J Am Acad Dermatol"},{"key":"211_CR2","volume-title":"Guideline on actinic keratoses","author":"E Stockfleth","year":"2010","unstructured":"Stockfleth E, Terhorst D, Braathen L, et al. Guideline on actinic keratoses. Berlin: European Dermatology Forum; 2010."},{"key":"211_CR3","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.2165\/11538670-000000000-00000","volume":"28","author":"EC Wilson","year":"2010","unstructured":"Wilson EC. Cost effectiveness of imiquimod 5% cream compared with methyl aminolevulinate-based photodynamic therapy in the treatment of non-hyperkeratotic, non-hypertrophic actinic (solar) keratoses: a decision tree model. Pharmacoeconomics. 2010;28:1055\u201364.","journal-title":"Pharmacoeconomics."},{"key":"211_CR4","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1468-3083.2011.04005.x","volume":"26","author":"A Pflugfelder","year":"2012","unstructured":"Pflugfelder A, Welter AK, Leiter U, et al. Open label randomized study comparing 3\u00a0months vs. 6\u00a0months treatment of actinic keratoses with 3% diclofenac in 2.5% hyaluronic acid gel: a trial of the German Dermatologic Cooperative Oncology Group. J Eur Acad Dermatol Venereol. 2012;26:48\u201353.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"211_CR5","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1159\/000112925","volume":"216","author":"P Bernard","year":"2008","unstructured":"Bernard P, Dupuy A, Sasco A, et al. Basal cell carcinomas and actinic keratoses seen in dermatological practice in France: a cross-sectional survey. Dermatology. 2008;216:194\u20139.","journal-title":"Dermatology"},{"key":"211_CR6","doi-asserted-by":"crossref","first-page":"451","DOI":"10.2165\/00019053-200927060-00002","volume":"27","author":"MV Neidecker","year":"2009","unstructured":"Neidecker MV, Davis-Ajami ML, Balkrishnan R, Feldman SR. Pharmacoeconomic considerations in treating actinic keratosis. Pharmacoeconomics. 2009;27:451\u201364.","journal-title":"Pharmacoeconomics."},{"key":"211_CR7","first-page":"39","volume":"3","author":"JL Cohen","year":"2010","unstructured":"Cohen JL. Actinic keratosis treatment as a key component of preventive strategies for nonmelanoma skin cancer. J Clin Aesthet Dermatol. 2010;3:39\u201344.","journal-title":"J Clin Aesthet Dermatol."},{"key":"211_CR8","first-page":"184","volume":"3","author":"E Perera","year":"2014","unstructured":"Perera E, McGuigan S, Sinclair R. Cost for the treatment of actinic keratosis on the rise in Australia. Version 2. F1000Res. 2014;3:184 (revised 2014 Aug 20).","journal-title":"F1000Res"},{"key":"211_CR9","first-page":"643","volume":"130","author":"S Pitk\u00e4nen","year":"2014","unstructured":"Pitk\u00e4nen S, Jeskanen L, Ylitalo L. Basalioomat, okasolusy\u00f6p\u00e4 ja sen esiasteet, miten hoidan? [Basal cell carcinoma, squamous cell carcinoma and premalignant skin lesions\u2014how to treat?]. Duodecim. 2014;130:643\u201353.","journal-title":"Duodecim."},{"key":"211_CR10","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1046\/j.1365-2133.1998.02560.x","volume":"139","author":"CA Frost","year":"1998","unstructured":"Frost CA, Green AC, Williams GM. The prevalence and determinants of solar keratoses at a subtropical latitude (Queensland, Australia). Br J Dermatol. 1998;139:1033\u20139.","journal-title":"Br J Dermatol"},{"key":"211_CR11","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1046\/j.1365-2133.2000.03541.x","volume":"142","author":"AA Memon","year":"2000","unstructured":"Memon AA, Tomenson JA, Bothwell J, Friedmann PS. Prevalence of solar damage and actinic keratosis in a Merseyside population. Br J Dermatol. 2000;142:1154\u20139.","journal-title":"Br J Dermatol"},{"issue":"1 Pt 2","key":"211_CR12","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1067\/mjd.2000.103342","volume":"42","author":"SJ Salasche","year":"2000","unstructured":"Salasche SJ. Epidemiology of actinic keratoses and squamous cell carcinoma. J Am Acad Dermatol. 2000;42(1 Pt 2):4\u20137.","journal-title":"J Am Acad Dermatol"},{"key":"211_CR13","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/j.1365-2133.1986.tb06644.x","volume":"115","author":"R Marks","year":"1986","unstructured":"Marks R, Foley P, Goodman G, Hage BH, Selwood TS. Spontaneous remission of solar keratoses: the case for conservative management. Br J Dermatol. 1986;115:649\u201355.","journal-title":"Br J Dermatol"},{"key":"211_CR14","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.1365-2133.1994.tb08544.x","volume":"131","author":"CA Frost","year":"1994","unstructured":"Frost CA, Green AC. Epidemiology of solar keratoses. Br J Dermatol. 1994;131:455\u201364.","journal-title":"Br J Dermatol"},{"key":"211_CR15","first-page":"1321","volume":"69","author":"A Kivisaari","year":"2014","unstructured":"Kivisaari A, K\u00e4h\u00e4ri VM. Miten tunnistan ja hoidan aurinkokeratoosin [Diagnosis and treatment of actinic keratosis.]. Finn Med J. 2014;69:1321\u20134.","journal-title":"Finn Med J."},{"key":"211_CR16","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1083\/jcb.117.1.47","volume":"1","author":"A Green","year":"1992","unstructured":"Green A. Changing patterns in incidence of non-melanoma skin cancer. Epithelial Cell Biol. 1992;1:47\u201351.","journal-title":"Epithelial Cell Biol"},{"key":"211_CR17","doi-asserted-by":"crossref","unstructured":"Lansbury L, Leonardi-Bee J, Perkins W, Goodacre T, Tweed JA, Bath-Hextall FJ. Interventions for non-metastatic squamous cell carcinoma of the skin. Cochrane Database Syst Rev. 2010;(4):CD007869.","DOI":"10.1002\/14651858.CD007869.pub2"},{"key":"211_CR18","unstructured":"Finnish Cancer Registry. Cancer in Finland 2008 and 2009. Cancer Statistics of the National Institute for Health and Welfare (THL). Helsinki: Cancer Society of Finland; 2011."},{"key":"211_CR19","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1067\/mjd.2003.186","volume":"48","author":"TS Housman","year":"2003","unstructured":"Housman TS, Feldman SR, Williford PM, et al. Skin cancer is among the most costly of all cancers to treat for the Medicare population. J Am Acad Dermatol. 2003;48:425\u20139.","journal-title":"J Am Acad Dermatol"},{"key":"211_CR20","doi-asserted-by":"crossref","first-page":"467","DOI":"10.2340\/00015555-0523","volume":"88","author":"G Tingh\u00f6g","year":"2008","unstructured":"Tingh\u00f6g G, Carlsson P, Synnerstad I, Rosdahl I. Societal cost of skin cancer in Sweden in 2005. Acta Derm Venereol. 2008;88:467\u201373.","journal-title":"Acta Derm Venereol"},{"key":"211_CR21","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1177\/1403494812456637","volume":"40","author":"R Sund","year":"2012","unstructured":"Sund R. Quality of the Finnish hospital discharge register: a systematic review. Scand J Public Health. 2012;40:505\u201315.","journal-title":"Scand J Public Health."},{"key":"211_CR22","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S0140-6736(09)61196-X","volume":"375","author":"V Madan","year":"2010","unstructured":"Madan V, Lear JT, Szeimies RM. Non-melanoma skin cancer. Lancet. 2010;375:673\u201385.","journal-title":"Lancet"},{"issue":"1","key":"211_CR23","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S0140-6736(88)91658-3","volume":"9","author":"R Marks","year":"1988","unstructured":"Marks R, Rennie G, Selwood TS. Malignant transformation of solar keratoses to squamous cell carcinoma. Lancet. 1988;9(1):795\u20137.","journal-title":"Lancet"},{"key":"211_CR24","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S0190-9622(97)70265-2","volume":"36","author":"JP Callen","year":"1997","unstructured":"Callen JP, Bickers DR, Moy RL. Actinic keratoses. J Am Acad Dermatol. 1997;36:650\u20133.","journal-title":"J Am Acad Dermatol"},{"issue":"5 Pt 1","key":"211_CR25","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1067\/mjd.2000.108373","volume":"43","author":"BA Lober","year":"2000","unstructured":"Lober BA, Lober CW, Accola J. Actinic keratosis is squamous cell carcinoma. J Am Acad Dermatol. 2000;43(5 Pt 1):881\u20132.","journal-title":"J Am Acad Dermatol"},{"issue":"1 Pt 2","key":"211_CR26","first-page":"8","volume":"42","author":"RL Moy","year":"2000","unstructured":"Moy RL. Clinical presentation of actinic keratoses and squamous cell carcinoma. J Am Acad Dermatol. 2000;42(1 Pt 2):8\u201310.","journal-title":"J Am Acad Dermatol"},{"key":"211_CR27","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.clindermatol.2003.12.006","volume":"22","author":"J Anwar","year":"2004","unstructured":"Anwar J, Wrone DA, Kimyai-Asadi A, Alam M. The development of actinic keratosis into invasive squamous cell carcinoma: evidence and evolving classification schemes. Clin Dermatol. 2004;22:189\u201396.","journal-title":"Clin Dermatol"},{"issue":"suppl","key":"211_CR28","first-page":"1","volume":"55","author":"B Berman","year":"2006","unstructured":"Berman B, Bienstock L, Kuritzky L, et al. Actinic keratoses: sequelae and treatments. Recommendations from a consensus panel. J Fam Pract. 2006;55(suppl):1\u20138.","journal-title":"J Fam Pract"},{"key":"211_CR29","first-page":"6","volume":"18","author":"P Quatresooz","year":"2008","unstructured":"Quatresooz P, Pi\u00e9rard-Franchimont C, Paquet P, Hubert P, Delvenne P, Pi\u00e9rard GE. Crossroads between actinic keratosis and squamous cell carcinoma, and novel pharmacological issues. Eur J Dermatol. 2008;18:6\u201310.","journal-title":"Eur J Dermatol."},{"key":"211_CR30","first-page":"651","volume":"18","author":"E Stockfleth","year":"2008","unstructured":"Stockfleth E, Ferrandiz C, Grob JJ, et al. Development of a treatment algorithm for actinic keratoses: a European Consensus. Eur J Dermatol. 2008;18:651\u20139.","journal-title":"Eur J Dermatol."},{"key":"211_CR31","first-page":"201","volume":"87","author":"SR Feldman","year":"2011","unstructured":"Feldman SR, Fleischer AB Jr. Progression of actinic keratosis to squamous cell carcinoma revisited: clinical and treatment implications. Cutis. 2011;87:201\u20137.","journal-title":"Cutis"},{"key":"211_CR32","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.clindermatol.2009.06.009","volume":"28","author":"CJ Ko","year":"2010","unstructured":"Ko CJ. Actinic keratosis: facts and controversies. Clin Dermatol. 2010;28:249\u201353.","journal-title":"Clin Dermatol"},{"key":"211_CR33","first-page":"4981","volume":"59","author":"K Airola","year":"2004","unstructured":"Airola K, Virolainen S, Saksela O. Ihon premalignit keratinosyyttimuutokset\u2014etiologia, kliininen kuva ja hoito [Premalignant keratoses\u2014aetiology, clinical picture and therapy.]. Finn Med J. 2004;59:4981\u20134.","journal-title":"Finn Med J."},{"key":"211_CR34","first-page":"71","volume":"121","author":"A Laukkanen","year":"2005","unstructured":"Laukkanen A, Rummukainen J, Kivinen P, Lappalainen K. Ihon okasolusy\u00f6p\u00e4 ja sen esiasteet. Duodecim. 2005;121:71\u20139.","journal-title":"Duodecim."},{"key":"211_CR35","first-page":"3095","volume":"64","author":"J Kotim\u00e4ki","year":"2009","unstructured":"Kotim\u00e4ki J. Fotodynaaminen hoito on merkitt\u00e4v\u00e4 vaihtoehto useissa p\u00e4\u00e4n ja kaulan alueen ihosy\u00f6viss\u00e4. Finn Med J. 2009;64:3095\u2013100.","journal-title":"Finn Med J."},{"key":"211_CR36","first-page":"163","volume":"22","author":"S Peltonen","year":"2012","unstructured":"Peltonen S, K\u00e4h\u00e4ri VM. Ihotautien muuttuvat haasteet. Erikoisl\u00e4\u00e4k\u00e4ri. 2012;22:163\u20136.","journal-title":"Ihotautien muuttuvat haasteet. Erikoisl\u00e4\u00e4k\u00e4ri."},{"key":"211_CR37","unstructured":"Hannuksela-Svahn A. Aktiininen keratoosi eli aurinkokeratoosi. [Actinic keratosis aka solar keratosis.] L\u00e4\u00e4k\u00e4rikirja Duodecim; 2014."},{"issue":"Suppl 2","key":"211_CR38","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1365-2133.2012.11086.x","volume":"167","author":"M Trakatelli","year":"2012","unstructured":"Trakatelli M, Siskou S, Proby C, et al. The patient journey: a report of skin cancer care across Europe. Br J Dermatol. 2012;167(Suppl 2):43\u201352.","journal-title":"Br J Dermatol"},{"key":"211_CR39","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.jaad.2009.01.008","volume":"60","author":"L Anderson","year":"2009","unstructured":"Anderson L, Schmieder GJ, Werschler WP, et al. Randomized, double-blind, double-dummy, vehicle-controlled study of ingenol mebutate gel 0.025% and 0.05% for actinic keratosis. J Am Acad Dermatol. 2009;60:934\u201343.","journal-title":"J Am Acad Dermatol"},{"key":"211_CR40","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1440-0960.2008.00497.x","volume":"50","author":"G Siller","year":"2009","unstructured":"Siller G, Gebauer K, Welburn P, Katsamas J, Ogbourne SM. PEP005 (ingenol mebutate) gel, a novel agent for the treatment of actinic keratosis: results of a randomized, double-blind, vehicle-controlled, multicentre, phase Iia study. Australas J Dermatol. 2009;50:16\u201322.","journal-title":"Australas J Dermatol"},{"key":"211_CR41","first-page":"AB106","volume":"62","author":"G Schmieder","year":"2010","unstructured":"Schmieder G. Multicenter, open-label, dose-area escalation, cohort study to evaluate the safety and tolerability of PEP005 (ingenol mebutate) gel 0.05% applied for two consecutive days to treatment area(s) of up to a total of 100 cm2 in patients with actinic keratoses. J Am Acad Dermatol. 2010;62:AB106.","journal-title":"J Am Acad Dermatol"},{"key":"211_CR42","unstructured":"Anderson L. Multicenter, randomized, parallel-group, double-blind, vehicle-controlled phase III study to evaluate the efficacy and safety of PEP005 (ingenol mebutate) gel, 0.05%, in patients with actinic keratoses on non-head locations. In: 22nd congress of dermatology; 2011: Abstract P2180."},{"key":"211_CR43","unstructured":"Berman B. A multicenter, randomized, parallel-group, double-blind, vehicle-controlled evaluation of the efficacy and safety of PEP005 (ingenol mebutate) gel, 0.015%, in patients with actinic keratoses on the head (face or scalp). In: 22nd World Congress of Dermatology; 2011: Abstract P2179."},{"key":"211_CR44","unstructured":"Lebwohl M. A randomized, parallel-group, double-blind, vehicle-controlled, multicenter study of the efficacy and safety of PEP005 (ingenol mebutate) gel, 0.015%, in patients with actinic keratoses on the head. In: 22nd World Congress of Dermatology; 2011: Abstract P2181."},{"key":"211_CR45","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1056\/NEJMoa1111170","volume":"366","author":"M Lebwohl","year":"2012","unstructured":"Lebwohl M, Swanson N, Anderson LL, Melgaard A, Xu Z, Berman B. Ingenol mebutate gel for actinic keratosis. N Engl J Med. 2012;366:1010\u20139.","journal-title":"N Engl J Med"},{"key":"211_CR46","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1001\/jamadermatol.2013.2766","volume":"149","author":"M Lebwohl","year":"2013","unstructured":"Lebwohl M, Shumack S, Stein Gold L, Melgaard A, Larsson T, Tyring SK. Long-term follow-up study of ingenol mebutate gel for the treatment of actinic keratoses. JAMA Dermatol. 2013;149:666\u201370.","journal-title":"JAMA Dermatol."},{"key":"211_CR47","first-page":"19","volume":"7","author":"L Anderson","year":"2014","unstructured":"Anderson L, Jarratt M, Schmieder G, Shumack S, Katsamas J, Welburn P. Tolerability and pharmacokinetics of ingenol mebutate 0.05% gel applied to treatment areas up to 100 cm(2) on the forearm(s) of patients with actinic keratosis. J Clin Aesthet Dermatol. 2014;7:19\u201329.","journal-title":"J Clin Aesthet Dermatol"},{"key":"211_CR48","first-page":"269","volume":"13","author":"MS Bettencourt","year":"2014","unstructured":"Bettencourt MS. Use of ingenol mebutate gel for actinic keratosis in patients in a community dermatology practice. J Drugs Dermatol. 2014;13:269\u201373.","journal-title":"J Drugs Dermatol"},{"key":"211_CR49","first-page":"1","volume":"8","author":"G Goldenberg","year":"2014","unstructured":"Goldenberg G, Berman B. Assessment of local skin reactions with a sequential regimen of cryosurgery followed by ingenol mebutate gel, 0.015%, in patients with actinic keratosis. Clin Cosmet Investig Dermatol. 2014;8:1\u20138.","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"211_CR50","doi-asserted-by":"crossref","unstructured":"Longo C, Neri L, Argenziano G, et al. Management of local skin reactions after the application of ingenol mebutate gel for the treatment of actinic keratosis: four illustrative cases. J Eur Acad Dermatol Venereol. 2014. doi: 10.1111\/jdv.12714 .","DOI":"10.1111\/jdv.12714"},{"key":"211_CR51","unstructured":"L\u00e4\u00e4kkeiden hintalautakunta. Terveystaloudellisen selvityksen laatiminen l\u00e4\u00e4kevalmisteen korvattavuus- ja tukkuhintahakemukseen. Helsinki: L\u00e4\u00e4kkeiden hintalautakunta; 2014."},{"key":"211_CR52","unstructured":"Behmane D, Lambot K, Irs A, Steikunas N. Baltic guideline for economic evaluation of pharmaceuticals (pharmacoeconomic analysis). 2002. Available from: http:\/\/www.ispor.org\/peguidelines\/source\/Baltic-PE-guideline.pdf"},{"key":"211_CR53","volume-title":"French guidelines for the economic evaluation of health care technologies","author":"Coll\u00e8ge des \u00c9conomistes de la Sant\u00e9","year":"2004","unstructured":"Coll\u00e8ge des \u00c9conomistes de la Sant\u00e9. French guidelines for the economic evaluation of health care technologies. Paris: CES; 2004."},{"key":"211_CR54","volume-title":"Guidelines for pharmacoeconomic research, updated version","author":"College voor zorgverzekeringen","year":"2006","unstructured":"College voor zorgverzekeringen. Guidelines for pharmacoeconomic research, updated version. Diemen: College voor zorgverzekeringen; 2006."},{"key":"211_CR55","volume-title":"Guidelines on Health Economic Evaluation","author":"IPF Institut f\u00fcr Pharma\u00f6konomische Forschung","year":"2006","unstructured":"IPF Institut f\u00fcr Pharma\u00f6konomische Forschung. Guidelines on Health Economic Evaluation. Vienna: IPF; 2006."},{"key":"211_CR56","unstructured":"Scottish Medicines Consortium. Guidance to Manufacturers for Completion of New Product Assessment Form (NPAF). SMC; 2007."},{"key":"211_CR57","unstructured":"Health Information and Quality Authority. Guidelines for the Economic Evaluation of Health Technologies in Ireland. HIQA; 2010."},{"key":"211_CR58","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s10198-010-0244-4","volume":"11","author":"J L\u00f3pez-Bastida","year":"2010","unstructured":"L\u00f3pez-Bastida J, Oliva J, Anto\u00f1anzas F, et al. Spanish recommendations on economic evaluation of health technologies. Eur J Health Econ. 2010;11:513\u201320.","journal-title":"Eur J Health Econ."},{"key":"211_CR59","volume-title":"Belgian guidelines for economic evaluations and budget impact analyses","author":"Belgian Health Care Knowledge Centre","year":"2012","unstructured":"Belgian Health Care Knowledge Centre. Belgian guidelines for economic evaluations and budget impact analyses. 2nd ed. Brussels: KCE; 2012.","edition":"2"},{"key":"211_CR60","unstructured":"Norwegian Medicines Agency (Statens legemiddelverk). Guidelines on how to conduct pharmacoeconomic analyses. NOMA; 2012."},{"key":"211_CR61","unstructured":"National Institute for Health and Care Excellence. Guide to the methods of technology appraisal 2013. NICE; 2013."},{"key":"211_CR62","first-page":"241","volume":"89","author":"B Berman","year":"2012","unstructured":"Berman B, Cohen DE, Amini S. What is the role of field-directed therapy in the treatment of actinic keratosis? Part 1: overview and investigational topical agents. Cutis. 2012;89:241\u201350.","journal-title":"Cutis"},{"key":"211_CR63","volume-title":"Ingenol mebutate, 150 & 500\u00a0micrograms\/g, gel (Picato\u00ae)","author":"Scottish Medicines Consortium","year":"2013","unstructured":"Scottish Medicines Consortium. Ingenol mebutate, 150 & 500\u00a0micrograms\/g, gel (Picato\u00ae). Glasgow: SMC; 2013."},{"key":"211_CR64","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1067\/mjd.2002.119649","volume":"47","author":"RM Szeimies","year":"2002","unstructured":"Szeimies RM, Karrer S, Radakovic-Fijan S, et al. Photodynamic therapy using topical methyl 5-aminolevulinate compared with cryotherapy for actinic keratosis: a prospective, randomized study. J Am Acad Dermatol. 2002;47:258\u201362.","journal-title":"J Am Acad Dermatol"},{"key":"211_CR65","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1080\/09546630310012118","volume":"14","author":"M Freeman","year":"2003","unstructured":"Freeman M, Vinciullo C, Francis D, et al. A comparison of photodynamic therapy using topical methyl aminolevulinate (Metvix) with single cycle cryotherapy in patients with actinic keratosis: a prospective, randomized study. J Dermatolog Treat. 2003;14:99\u2013106.","journal-title":"J Dermatolog Treat."},{"key":"211_CR66","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1111\/j.1365-2133.2006.07470.x","volume":"155","author":"C Morton","year":"2006","unstructured":"Morton C, Campbell S, Gupta G, et al. Intraindividual, right-left comparison of topical methyl aminolaevulinate-photodynamic therapy and cryotherapy in subjects with actinic keratoses: a multicentre, randomized controlled study. Br J Dermatol. 2006;155:1029\u201336.","journal-title":"Br J Dermatol"},{"key":"211_CR67","first-page":"669","volume":"7","author":"JM Berlin","year":"2008","unstructured":"Berlin JM, Rigel DS. Diclofenac sodium 3% gel in the treatment of actinic keratosis postcryosurgery. J Drugs Dermatol. 2008;7:669\u201373.","journal-title":"J Drugs Dermatol"},{"key":"211_CR68","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1111\/j.1365-2133.2008.08488.x","volume":"158","author":"R Kaufmann","year":"2008","unstructured":"Kaufmann R, Spelman L, Weightman W, et al. Multicentre intraindividual randomized trial of topical methyl aminolaevulinate-photodynamic therapy vs. cryotherapy for multiple actinic keratoses on the extremities. Br J Dermatol. 2008;158:994\u20139.","journal-title":"Br J Dermatol"},{"key":"211_CR69","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/j.1600-0625.2008.00770.x","volume":"18","author":"A Hauschild","year":"2009","unstructured":"Hauschild A, Popp G, Stockfleth E, et al. Effective photodynamic therapy of actinic keratoses on the head and face with a novel, self-adhesive 5-aminolaevulinic acid patch. Exp Dermatol. 2009;18:116\u201321.","journal-title":"Exp Dermatol"},{"key":"211_CR70","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1111\/j.1365-2133.2009.09040.x","volume":"160","author":"A Hauschild","year":"2009","unstructured":"Hauschild A, Stockfleth E, Popp G, et al. Optimization of photodynamic therapy with a novel self-adhesive 5-aminolaevulinic acid patch: results of two randomized controlled phase III studies. Br J Dermatol. 2009;160:1066\u201374.","journal-title":"Br J Dermatol"},{"key":"211_CR71","first-page":"128","volume":"7","author":"C Huyke","year":"2009","unstructured":"Huyke C, Reuter J, R\u00f6dig M, et al. Therapie von aktinischen Keratosen mit einem neuen Betulin-basierten Oleogel; eine prospektive, randomisierte, vergleichende Pilotstudie. Treatment of actinic keratoses with a novel botulin-based oleogel. A prospective, randomized, comparative pilot study. J Dtsch Dermatol Ges. 2009;7:128\u201333.","journal-title":"J Dtsch Dermatol Ges."},{"key":"211_CR72","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1440-0960.1997.tb01693.x","volume":"38","author":"LE McEwan","year":"1997","unstructured":"McEwan LE, Smith JG. Topical diclofenac\/hyaluronic acid gel in the treatment of solar keratoses. Australas J Dermatol. 1997;38:187\u20139.","journal-title":"Australas J Dermatol"},{"key":"211_CR73","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1046\/j.1365-4362.2001.01324.x","volume":"40","author":"JE Wolf Jr","year":"2001","unstructured":"Wolf JE Jr, Taylor JR, Tschen E, Kang S. Topical 3.0% diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses. Int J Dermatol. 2001;40:709\u201313.","journal-title":"Int J Dermatol"},{"key":"211_CR74","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1046\/j.1365-2133.2002.04561.x","volume":"146","author":"JK Rivers","year":"2002","unstructured":"Rivers JK, Arlette J, Shear N, Guenther L, Carey W, Poulin Y. Topical treatment of actinic keratoses with 3.0% diclofenac in 2.5% hyaluronan gel. Br J Dermatol. 2002;146:94\u2013100.","journal-title":"Br J Dermatol"},{"key":"211_CR75","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1046\/j.1440-0960.2002.00635.x","volume":"44","author":"K Gebauer","year":"2003","unstructured":"Gebauer K, Brown P, Varigos G. Topical diclofenac in hyaluronan gel for the treatment of solar keratoses. Australas J Dermatol. 2003;44:40\u20133.","journal-title":"Australas J Dermatol"},{"key":"211_CR76","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1080\/09546630701818870","volume":"19","author":"O Kose","year":"2008","unstructured":"Kose O, Koc E, Erbil AH, Caliskan E, Kurumlu Z. Comparison of the efficacy and tolerability of 3% diclofenac sodium gel and 5% imiquimod cream in the treatment of actinic keratosis. J Dermatolog Treat. 2008;19:159\u201363.","journal-title":"J Dermatolog Treat."},{"key":"211_CR77","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.jaad.2009.06.020","volume":"62","author":"CW Hanke","year":"2010","unstructured":"Hanke CW, Beer KR, Stockfleth E, Wu J, Rosen T, Levy S. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 3-week cycles. J Am Acad Dermatol. 2010;62:573\u201381.","journal-title":"J Am Acad Dermatol"},{"key":"211_CR78","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.jaad.2009.07.004","volume":"62","author":"N Swanson","year":"2010","unstructured":"Swanson N, Abramovits W, Berman B, Kulp J, Rigel DS, Levy S. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 2-week cycles. J Am Acad Dermatol. 2010;62:582\u201390.","journal-title":"J Am Acad Dermatol"},{"key":"211_CR79","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1046\/j.1440-0960.2003.00003.x","volume":"44","author":"K Chen","year":"2003","unstructured":"Chen K, Yap LM, Marks R, Shumack S. Short-course therapy with imiquimod 5% cream for solar keratoses: a randomized controlled trial. Australas J Dermatol. 2003;44:250\u20135.","journal-title":"Australas J Dermatol"},{"key":"211_CR80","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.jaad.2003.12.010","volume":"50","author":"M Lebwohl","year":"2004","unstructured":"Lebwohl M, Dinehart S, Whiting D, et al. Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials. J Am Acad Dermatol. 2004;50:714\u201321.","journal-title":"J Am Acad Dermatol"},{"key":"211_CR81","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.jaad.2004.02.022","volume":"51","author":"RM Szeimies","year":"2004","unstructured":"Szeimies RM, Gerritsen MJ, Gupta G, et al. Imiquimod 5% cream for the treatment of actinic keratosis: results from a phase III, randomized, double-blind, vehicle-controlled, clinical trial with histology. J Am Acad Dermatol. 2004;51:547\u201355.","journal-title":"J Am Acad Dermatol"},{"key":"211_CR82","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1001\/archderm.141.4.467","volume":"141","author":"N Korman","year":"2005","unstructured":"Korman N, Moy R, Ling M, et al. Dosing with 5% imiquimod cream 3 times per week for the treatment of actinic keratosis: results of two phase 3, randomized, double-blind, parallel-group, vehicle-controlled trials. Arch Dermatol. 2005;141:467\u201373.","journal-title":"Arch Dermatol"},{"key":"211_CR83","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1365-2133.2005.06932.x","volume":"154","author":"T Ooi","year":"2006","unstructured":"Ooi T, Barnetson RS, Zhuang L, et al. Imiquimod-induced regression of actinic keratosis is associated with infiltration by T lymphocytes and dendritic cells: a randomized controlled trial. Br J Dermatol. 2006;154:72\u20138.","journal-title":"Br J Dermatol"},{"key":"211_CR84","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1365-2133.2007.07942.x","volume":"157","author":"A Alomar","year":"2007","unstructured":"Alomar A, Bichel J, McRae S. Vehicle-controlled, randomized, double-blind study to assess safety and efficacy of imiquimod 5% cream applied once daily 3\u00a0days per week in one or two courses of treatment of actinic keratoses on the head. Br J Dermatol. 2007;157:133\u201341.","journal-title":"Br J Dermatol"},{"issue":"Suppl 2","key":"211_CR85","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1365-2133.2007.08269.x","volume":"157","author":"C Ulrich","year":"2007","unstructured":"Ulrich C, Bichel J, Euvrard S, et al. Topical immunomodulation under systemic immunosuppression: results of a keratoses, randomized, placebo-controlled safety and efficacy study of imiquimod 5% cream for the treatment of actinic keratoses in kidney, heart, and liver transplant patients. Br J Dermatol. 2007;157(Suppl 2):25\u201331.","journal-title":"Br J Dermatol"},{"key":"211_CR86","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1111\/j.1365-2133.2009.09260.x","volume":"161","author":"K Gebauer","year":"2009","unstructured":"Gebauer K, Shumack S, Cowen PS. Effect of dosing frequency on the safety and efficacy of imiquimod 5% cream for treatment of actinic keratosis on the forearms and hands: a phase II, randomized placebo-controlled trial. Br J Dermatol. 2009;161:897\u2013903.","journal-title":"Br J Dermatol"},{"key":"211_CR87","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1067\/mjd.2003.49","volume":"48","author":"DM Pariser","year":"2003","unstructured":"Pariser DM, Lowe NJ, Stewart DM, et al. Photodynamic therapy with topical methyl aminolevulinate for actinic keratosis: results of a prospective randomized multicenter trial. J Am Acad Dermatol. 2003;48:227\u201332.","journal-title":"J Am Acad Dermatol"},{"key":"211_CR88","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1080\/00015550510032887","volume":"85","author":"M Tarstedt","year":"2005","unstructured":"Tarstedt M, Rosdahl I, Berne B, Svanberg K, Wennberg AM. A randomized multicenter study to compare two treatment regimens of topical methyl aminolevulinate (Metvix)-PDT in actinic keratosis of the face and scalp. Acta Derm Venereol. 2005;85:424\u20138.","journal-title":"Acta Derm Venereol"},{"key":"211_CR89","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.jaad.2008.05.031","volume":"59","author":"D Pariser","year":"2008","unstructured":"Pariser D, Loss R, Jarratt M, et al. Topical methyl-aminolevulinate photodynamic therapy using red light-emitting diode light for treatment of multiple actinic keratoses: a randomized, double-blind, placebo-controlled study. J Am Acad Dermatol. 2008;59:569\u201376.","journal-title":"J Am Acad Dermatol"},{"key":"211_CR90","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1111\/j.1468-3083.2008.03029.x","volume":"23","author":"LR Braathen","year":"2009","unstructured":"Braathen LR, Paredes BE, Saksela O, et al. Short incubation with methyl aminolevulinate for photodynamic therapy of actinic keratoses. J Eur Acad Dermatol Venereol. 2009;23:550\u20135.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"211_CR91","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1111\/j.1524-4725.2009.01096.x","volume":"35","author":"RM Szeimies","year":"2009","unstructured":"Szeimies RM, Matheson RT, Davis SA, et al. Topical methyl aminolevulinate photodynamic therapy using red light-emitting diode light for multiple actinic keratoses: a randomized study. Dermatol Surg. 2009;35:586\u201392.","journal-title":"Dermatol Surg"},{"key":"211_CR92","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1001\/archderm.140.7.813","volume":"140","author":"J Jorizzo","year":"2004","unstructured":"Jorizzo J, Weiss J, Furst K, VandePol C, Levy SF. Effect of a 1-week treatment with 0.5% topical fluorouracil on occurrence of actinic keratosis after cryosurgery: a randomized, vehicle-controlled clinical trial. Arch Dermatol. 2004;140:813\u20136.","journal-title":"Arch Dermatol"},{"key":"211_CR93","first-page":"133","volume":"5","author":"J Jorizzo","year":"2006","unstructured":"Jorizzo J, Weiss J, Vamvakias G. One-week treatment with 0.5% fluorouracil cream prior to cryosurgery in patients with actinic keratoses: a double-blind, vehicle-controlled, long-term study. J Drugs Dermatol. 2006;5:133\u20139.","journal-title":"J Drugs Dermatol"},{"key":"211_CR94","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jaad.2007.01.047","volume":"57","author":"J Jorizzo","year":"2007","unstructured":"Jorizzo J, Dinehart S, Matheson R, et al. Vehicle-controlled, double-blind, randomized study of imiquimod 5% cream applied 3\u00a0days per week in one or two courses of treatment for actinic keratoses on the head. J Am Acad Dermatol. 2007;57:265\u20138.","journal-title":"J Am Acad Dermatol"},{"key":"211_CR95","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1007\/s11136-006-0020-1","volume":"15","author":"SI Saarni","year":"2006","unstructured":"Saarni SI, H\u00e4rk\u00e4nen T, Sintonen H, et al. The impact of 29 chronic conditions on health-related quality of life: a general population survey in Finland using 15D and EQ-5D. Qual Life Res. 2006;15:1403\u201314.","journal-title":"Qual Life Res"},{"key":"211_CR96","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1590\/S0365-05962009000200007","volume":"84","author":"MW Ludwig","year":"2009","unstructured":"Ludwig MW, Oliveira Mda S, Muller MC, Moraes JF. Quality of life and site of the lesion in dermatological patients. An Bras Dermatol. 2009;84:143\u201350.","journal-title":"An Bras Dermatol."},{"key":"211_CR97","unstructured":"Suomen virallinen tilasto (SVT): Julkisten menojen hintaindeksi [verkkojulkaisu]. [Index for communal services]. Helsinki: Tilastokeskus; 2014."},{"key":"211_CR98","doi-asserted-by":"crossref","first-page":"6","DOI":"10.2174\/1876824501103010006","volume":"3","author":"T Hallinen","year":"2011","unstructured":"Hallinen T, Soini EJ. The impact of the pharmaceutical pricing system on cost-effectiveness results: Finnish analysis. Open Pharmacoeconomics Health Econ J. 2011;3:6\u201310.","journal-title":"Open Pharmacoeconomics Health Econ J."},{"key":"211_CR99","unstructured":"Kapiainen S, V\u00e4is\u00e4nen A, Haula T. Terveyden-ja sosiaalihuollon yksikk\u00f6kustannukset Suomessa vuonna 2011. [Health and social care unit costs in Finland in year 2011.] Tampere: Terveyden ja hyvinvoinnin laitos; 2014."},{"key":"211_CR100","unstructured":"Hujanen T, Kapiainen S, Tuominen U, Pekurinen M. Terveydenhuollon yksikk\u00f6kustannukset Suomessa vuonna 2006. [Health care unit costs in Finland in year 2006.] Helsinki: Stakes; 2008."},{"key":"211_CR101","unstructured":"Suomen virallinen tilasto (SVT): Kuluttajahintaindeksi [verkkojulkaisu]. [Consumer price index]. Helsinki: Tilastokeskus; 2014."},{"key":"211_CR102","unstructured":"Tilastokeskus. Ty\u00f6voimatutkimus. [Labor force survey]. Helsinki: Tilastokeskus; 2011."},{"key":"211_CR103","unstructured":"Suomen virallinen tilasto (SVT): Ansiotasoindeksi [verkkojulkaisu]. [Income index]. Helsinki: Tilastokeskus; 2014."},{"key":"211_CR104","doi-asserted-by":"crossref","first-page":"e96829","DOI":"10.1371\/journal.pone.0096829","volume":"9","author":"S Vegter","year":"2014","unstructured":"Vegter S, Tolley K. A network meta-analysis of the relative efficacy of treatments for actinic keratosis of the face or scalp in Europe. PLoS One. 2014;9:e96829.","journal-title":"PLoS One"},{"issue":"2 Suppl","key":"211_CR105","first-page":"30","volume":"70","author":"AK Gupta","year":"2002","unstructured":"Gupta AK. The management of actinic keratoses in the United States with topical fluorouracil: a pharmacoeconomic evaluation. Cutis. 2002;70(2 Suppl):30\u20136.","journal-title":"Cutis"},{"key":"211_CR106","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2165\/00019053-200422020-00002","volume":"22","author":"MK Higashi","year":"2004","unstructured":"Higashi MK, Veenstra DL, Langley PC. Health economic evaluation of non-melanoma skin cancer and actinic keratosis. Pharmacoeconomics. 2004;22:83\u201394.","journal-title":"Pharmacoeconomics."},{"key":"211_CR107","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1111\/j.1365-2133.2006.07483.x","volume":"155","author":"K Caekelbergh","year":"2006","unstructured":"Caekelbergh K, Annemans L, Lambert J, Roelandts R. Economic evaluation of methyl aminolaevulinate-based photodynamic therapy in the management of actinic keratosis and basal cell carcinoma. Br J Dermatol. 2006;155:784\u201390.","journal-title":"Br J Dermatol"},{"key":"211_CR108","first-page":"1045","volume":"32","author":"L Warino","year":"2006","unstructured":"Warino L, Tusa M, Camacho F, Teuschler H, Fleischer AB Jr, Feldman SR. Frequency and cost of actinic keratosis treatment. Dermatol Surg. 2006;32:1045\u20139.","journal-title":"Dermatol Surg"},{"key":"211_CR109","first-page":"539","volume":"18","author":"L Annemans","year":"2008","unstructured":"Annemans L, Caekelbergh K, Roelandts R, et al. Real-life practice study of the clinical outcome and cost-effectiveness of photodynamic therapy using methyl aminolevulinate (MAL-PDT) in the management of actinic keratosis and basal cell carcinoma. Eur J Dermatol. 2008;18:539\u201346.","journal-title":"Eur J Dermatol."},{"key":"211_CR110","first-page":"23","volume":"7","author":"MH Gold","year":"2008","unstructured":"Gold MH. Pharmacoeconomic analysis of the treatment of multiple actinic keratoses. J Drugs Dermatol. 2008;7:23\u20135.","journal-title":"J Drugs Dermatol"},{"key":"211_CR111","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1080\/09546630902887211","volume":"20","author":"D Muston","year":"2009","unstructured":"Muston D, Downs A, Rives V. An economic evaluation of topical treatments for actinic keratosis. J Dermatolog Treat. 2009;20:266\u201375.","journal-title":"J Dermatolog Treat."},{"key":"211_CR112","first-page":"573","volume":"145","author":"GL Colombo","year":"2010","unstructured":"Colombo GL, Chimenti S, Di Matteo S, et al. Cost-effectiveness analysis of topical treatments for actinic keratosis in the perspective of the Italian health care system. G Ital Dermatol Venereol. 2010;145:573\u201381.","journal-title":"G Ital Dermatol Venereol."},{"key":"211_CR113","doi-asserted-by":"crossref","first-page":"298","DOI":"10.3109\/09546631003797080","volume":"22","author":"E Wilson","year":"2011","unstructured":"Wilson E, et al. Economic evaluations based on decision models: a response to Muston et al. J Dermatolog Treat. 2011;22:298\u2013301.","journal-title":"J Dermatolog Treat."},{"issue":"Suppl 1","key":"211_CR114","doi-asserted-by":"crossref","first-page":"I82","DOI":"10.1136\/ard.58.2008.i82","volume":"58","author":"C Bombardier","year":"1999","unstructured":"Bombardier C, Maetzel A. Pharmacoeconomic evaluation of new treatments: efficacy versus effectiveness studies? Ann Rheum Dis. 1999;58(Suppl 1):I82\u20135.","journal-title":"Ann Rheum Dis"},{"issue":"12 Pt 2","key":"211_CR115","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.7326\/0003-4819-142-12_Part_2-200506211-00006","volume":"142","author":"PL Santaguida","year":"2005","unstructured":"Santaguida PL, Helfand M, Raina P. Challenges in systematic reviews that evaluate drug efficacy or effectiveness. Ann Intern Med. 2005;142(12 Pt 2):1066\u201372.","journal-title":"Ann Intern Med"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-015-0211-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,23]],"date-time":"2017-06-23T08:16:03Z","timestamp":1498205763000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-015-0211-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":115,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["211"],"URL":"https:\/\/doi.org\/10.1007\/s12325-015-0211-7","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5]]}}}